View Financial HealthSitara Peroxide 배당 및 자사주 매입배당 기준 점검 0/6Sitara Peroxide 배당금을 지급한 기록이 없습니다.핵심 정보n/a배당 수익률n/a자사주 매입 수익률총 주주 수익률n/a미래 배당 수익률n/a배당 성장률n/a다음 배당 지급일n/a배당락일n/a주당 배당금n/a배당 성향n/a최근 배당 및 자사주 매입 업데이트업데이트 없음모든 업데이트 보기Recent updatesValuation Update With 7 Day Price Move • Apr 27Investor sentiment improves as stock rises 15%After last week's 15% share price gain to PK₨59.90, the stock trades at a trailing P/E ratio of 22.1x. Average trailing P/E is 11x in the Chemicals industry in Pakistan. Total returns to shareholders of 328% over the past three years.공시 • Apr 22Sitara Peroxide Limited to Report Q3, 2026 Results on Apr 29, 2026Sitara Peroxide Limited announced that they will report Q3, 2026 results on Apr 29, 2026공시 • Feb 24Sitara Peroxide Limited to Report First Half, 2026 Results on Feb 28, 2026Sitara Peroxide Limited announced that they will report first half, 2026 results on Feb 28, 2026New Risk • Feb 17New major risk - Market cap sizeThe company's market capitalization is less than US$10m. Market cap: PK₨2.79b (US$9.97m) This is considered a major risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (14% average weekly change). Earnings have declined by 25% per year over the past 5 years. Revenue is less than US$1m. Market cap is less than US$10m (PK₨2.79b market cap, or US$9.97m).Board Change • Feb 13Less than half of directors are independentFollowing the recent departure of a director, there are only 2 independent directors on the board. The company's board is composed of: 2 independent directors. 5 non-independent directors. Independent Director Saim Bin Saeed was the last independent director to join the board, commencing their role in 2022. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.공시 • Jan 20Sitara Peroxide Limited to Report Q1, 2026 Results on Jan 27, 2026Sitara Peroxide Limited announced that they will report Q1, 2026 results at 12:30 PM, Pakistan Standard Time on Jan 27, 2026공시 • Jan 08Sitara Peroxide Limited Announces Directorate AppointmentsSitara Peroxide Limited, at the EGM held on January 7, 2026 approved appointment of Mr. Muhammad Bin Imran and Mr. Muhammad Iqbal as directors.공시 • Oct 31Sitara Peroxide Limited to Report Fiscal Year 2025 Results on Nov 07, 2025Sitara Peroxide Limited announced that they will report fiscal year 2025 results at 9:30 AM, Pakistan Standard Time on Nov 07, 2025New Risk • Sep 12New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of Pakistani stocks, typically moving 9.3% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (9.3% average weekly change). Revenue has declined by 98% over the past year. Revenue is less than US$1m (PK₨15m revenue, or US$53k). Market cap is less than US$10m (PK₨1.45b market cap, or US$5.14m).New Risk • Aug 09New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Pakistani stocks, typically moving 8.5% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risks Revenue has declined by 98% over the past year. Revenue is less than US$1m (PK₨15m revenue, or US$53k). Market cap is less than US$10m (PK₨970.9m market cap, or US$3.44m). Minor Risk Share price has been volatile over the past 3 months (8.5% average weekly change).공시 • Aug 01Sitara Peroxide Limited, Annual General Meeting, Aug 22, 2025Sitara Peroxide Limited, Annual General Meeting, Aug 22, 2025.New Risk • Jul 01New major risk - Financial data availabilityThe company has not reported any financial data. This is considered a major risk. With no or incomplete audited reported financial data, it is virtually impossible to assess the company's investment potential. Currently, the following risks have been identified for the company: Major Risks No financial data reported. Market cap is less than US$10m (PK₨820.4m market cap, or US$2.89m).New Risk • Mar 30New major risk - Financial data availabilityThe company has not reported any financial data. This is considered a major risk. With no or incomplete audited reported financial data, it is virtually impossible to assess the company's investment potential. Currently, the following risks have been identified for the company: Major Risks No financial data reported. Market cap is less than US$10m (PK₨664.0m market cap, or US$2.37m).Reported Earnings • Dec 19First quarter 2024 earnings released: PK₨1.43 loss per share (vs PK₨1.98 loss in 1Q 2023)First quarter 2024 results: PK₨1.43 loss per share (improved from PK₨1.98 loss in 1Q 2023). Revenue: PK₨15.9m (down 95% from 1Q 2023). Net loss: PK₨78.8m (loss narrowed 28% from 1Q 2023).Reported Earnings • Sep 27Full year 2023 earnings released: PK₨14.39 loss per share (vs PK₨6.19 loss in FY 2022)Full year 2023 results: PK₨14.39 loss per share (further deteriorated from PK₨6.19 loss in FY 2022). Revenue: PK₨824.0m (down 53% from FY 2022). Net loss: PK₨792.8m (loss widened 132% from FY 2022).공시 • Sep 27Sitara Peroxide Limited, Annual General Meeting, Oct 10, 2024Sitara Peroxide Limited, Annual General Meeting, Oct 10, 2024.New Risk • Aug 26New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Pakistani stocks, typically moving 7.0% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risks Latest financial reports are more than 1 year old (reported March 2023 fiscal period end). Revenue has declined by 64% over the past year. Market cap is less than US$10m (PK₨783.0m market cap, or US$2.81m). Minor Risks Share price has been volatile over the past 3 months (7.0% average weekly change). Revenue is less than US$5m (PK₨720m revenue, or US$2.6m).공시 • Jul 23Sitara Peroxide Limited, Annual General Meeting, Jul 26, 2024Sitara Peroxide Limited, Annual General Meeting, Jul 26, 2024, at 15:00 Pakistan Standard Time. Agenda: To consider the pending approval of the audited financial statments along with subsequent developments and way-forward; to consider the pending approval of the balancing, modernization and replacement of the company, the financial arrangementas and way-forward; and to consider other matters.New Risk • May 05New major risk - Financial data availabilityThe company's latest financial reports are more than a year old. Last reported fiscal period ended March 2023. This is considered a major risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. In the worst case scenario, it may be facing other major going concern issues jeopardizing its viability as a listed company. Currently, the following risks have been identified for the company: Major Risks Latest financial reports are more than 1 year old (reported March 2023 fiscal period end). Revenue has declined by 64% over the past year. Market cap is less than US$10m (PK₨771.4m market cap, or US$2.77m). Minor Risk Revenue is less than US$5m (PK₨720m revenue, or US$2.6m).New Risk • Nov 21New minor risk - Financial data availabilityThe company's latest financial reports are more than 6 months old. Last reported fiscal period ended March 2023. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-PK₨139m free cash flow). Share price has been highly volatile over the past 3 months (8.8% average weekly change). Earnings have declined by 56% per year over the past 5 years. Market cap is less than US$10m (PK₨933.9m market cap, or US$3.27m). Minor Risks Latest financial reports are more than 6 months old (reported March 2023 fiscal period end). Revenue is less than US$5m (PK₨720m revenue, or US$2.5m).New Risk • Oct 18New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Pakistani stocks, typically moving 6.2% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-PK₨139m free cash flow). Earnings have declined by 56% per year over the past 5 years. Market cap is less than US$10m (PK₨750.5m market cap, or US$2.71m). Minor Risks Share price has been volatile over the past 3 months (6.2% average weekly change). Revenue is less than US$5m (PK₨720m revenue, or US$2.6m).Reported Earnings • Apr 08Second quarter 2023 earnings released: PK₨2.01 loss per share (vs PK₨0.13 profit in 2Q 2022)Second quarter 2023 results: PK₨2.01 loss per share (down from PK₨0.13 profit in 2Q 2022). Revenue: PK₨70.6m (down 89% from 2Q 2022). Net loss: PK₨111.0m (down PK₨118.2m from profit in 2Q 2022). Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 101 percentage points per year, which is a significant difference in performance.Board Change • Nov 16Less than half of directors are independentThere is 1 new director who has joined the board in the last 3 years. The new board member was an independent director. The company's board is composed of: 1 new director. 6 experienced directors. No highly experienced directors. 2 independent directors (5 non-independent directors). Independent Director Saim Bin Saeed was the last independent director to join the board, commencing their role in 2022. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment.공시 • Nov 12Sitara Peroxide Limited Appoints Yasir Ahmed Awan as ChairmanSitara Peroxide Limited announced that Mr. Yasir Ahmed Awan has been appointed as Chairman of the Board of Directors of the Company and Mr. Imran Ghafoor as Chief Executive Officer for a term of three years.공시 • Aug 19Sitara Peroxide Limited Appoints Saim Bin Saeed as DirectorSitara Peroxide Limited informed Pakistan Stock Exchange that Mr. Saim Bin Saeed has been appointed as Director of the company with effect from August 17, 2022 in place of Mr. Mahmood Ahmad.공시 • Jun 03Sitara Peroxide Limited Announces Resignation of Mahmood Ahmad as DirectorSitara Peroxide Limited informed Pakistan Stock Exchange that Mr. Mahmood Ahmad has resigned from the post of Director of the company with effect from May 30, 2022.Board Change • Apr 27Less than half of directors are independentNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 7 experienced directors. No highly experienced directors. 2 independent directors (5 non-independent directors). Non-Executive Director Ejaz Hussain was the last director to join the board, commencing their role in 2016. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment.Reported Earnings • Nov 01First quarter 2022 earnings released: PK₨1.80 loss per share (vs PK₨0.92 profit in 1Q 2021)The company reported a poor first quarter result with weaker earnings, revenues and control over costs. First quarter 2022 results: Revenue: PK₨450.5m (down 21% from 1Q 2021). Net loss: PK₨99.0m (down 294% from profit in 1Q 2021). Over the last 3 years on average, earnings per share has fallen by 49% per year but the company’s share price has only fallen by 15% per year, which means it has not declined as severely as earnings.Price Target Changed • Oct 07Price target decreased to PK₨31.00Down from PK₨36.50, the current price target is provided by 1 analyst. New target price is 43% above last closing price of PK₨21.62. Stock is down 6.3% over the past year.Reported Earnings • Sep 28Full year 2021 earnings released: EPS PK₨0.63 (vs PK₨1.35 in FY 2020)The company reported a soft full year result with weaker earnings and profit margins, although revenues improved. Full year 2021 results: Revenue: PK₨1.87b (up 6.9% from FY 2020). Net income: PK₨34.7m (down 53% from FY 2020). Profit margin: 1.9% (down from 4.3% in FY 2020). Over the last 3 years on average, earnings per share has fallen by 5% per year but the company’s share price has fallen by 14% per year, which means it is performing significantly worse than earnings.Valuation Update With 7 Day Price Move • Sep 27Investor sentiment deteriorated over the past weekAfter last week's 16% share price decline to PK₨21.00, the stock trades at a trailing P/E ratio of 5.7x. Average forward P/E is 17x in the Chemicals industry in Pakistan. Total loss to shareholders of 32% over the past three years.Executive Departure • Jul 13Chief Financial Officer Kamran Zahoor has left the companyDuring their tenure, the company went from making losses to turning a profit. On the 30th of June, Kamran Zahoor left the company after 3.3 in the role. We don't have any record of a personal shareholding under Kamran's name. Kamran is the only executive to leave the company over the last 12 months.Reported Earnings • May 02Third quarter 2021 earnings released: EPS PK₨0.44 (vs PK₨0.15 in 3Q 2020)The company reported a decent third quarter result with improved earnings and profit margins, although revenues were weaker. Third quarter 2021 results: Revenue: PK₨447.8m (down 3.8% from 3Q 2020). Net income: PK₨24.3m (up 200% from 3Q 2020). Profit margin: 5.4% (up from 1.7% in 3Q 2020). The increase in margin was driven by lower expenses. Over the last 3 years on average, earnings per share has increased by 30% per year but the company’s share price has only increased by 8% per year, which means it is significantly lagging earnings growth.Reported Earnings • Feb 28Second quarter 2021 earnings released: EPS PK₨0.83 (vs PK₨0.40 loss in 2Q 2020)The company reported a decent second quarter result with improved earnings and profit margins, although revenues were weaker. Second quarter 2021 results: Revenue: PK₨497.2m (down 7.4% from 2Q 2020). Net income: PK₨45.6m (up PK₨67.8m from 2Q 2020). Profit margin: 9.2% (up from net loss in 2Q 2020). The move to profitability was driven by lower expenses. Over the last 3 years on average, earnings per share has increased by 43% per year but the company’s share price has only increased by 19% per year, which means it is significantly lagging earnings growth.Valuation Update With 7 Day Price Move • Feb 01Investor sentiment improved over the past weekAfter last week's 19% share price gain to PK₨32.76, the stock is trading at a trailing P/E ratio of 15.3x, up from the previous P/E ratio of 12.8x. This compares to an average P/E of 14x in the Chemicals industry in Pakistan. Total returns to shareholders over the past three years are 66%.Is New 90 Day High Low • Jan 27New 90-day high: PK₨30.16The company is up 36% from its price of PK₨22.13 on 29 October 2020. The Pakistani market is up 10.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Chemicals industry, which is up 5.0% over the same period.Valuation Update With 7 Day Price Move • Jan 06Investor sentiment improved over the past weekAfter last week's 17% share price gain to PK₨26.91, the stock is trading at a trailing P/E ratio of 12.5x, up from the previous P/E ratio of 10.7x. This compares to an average P/E of 13x in the Chemicals industry in Pakistan. Total returns to shareholders over the past three years are 59%.Is New 90 Day High Low • Jan 05New 90-day high: PK₨25.04The company is up 8.0% from its price of PK₨23.22 on 07 October 2020. The Pakistani market is up 11% over the last 90 days, indicating the company underperformed over that time. However, it outperformed the Chemicals industry, which is up 7.0% over the same period.Reported Earnings • Oct 23First quarter earnings releasedOver the last 12 months the company has reported total profits of PK₨119.9m, up 67% from the prior year. Total revenue was PK₨1.92b over the last 12 months, up 2.3% from the prior year.Reported Earnings • Oct 06Full year earnings released - EPS PK₨1.35Over the last 12 months the company has reported total profits of PK₨74.2m, down 64% from the prior year. Total revenue was PK₨1.75b over the last 12 months, down 14% from the prior year. Profit margins were 4.3%, which is lower than the 10% margin from last year. The decrease in margin was driven by lower revenue.Reported Earnings • Sep 30Full year earnings released - EPS PK₨1.35Over the last 12 months the company has reported total profits of PK₨74.2m, down 64% from the prior year. Total revenue was PK₨1.75b over the last 12 months, down 14% from the prior year. Profit margins were 4.3%, which is lower than the 10% margin from last year. The decrease in margin was driven by lower revenue.지급의 안정성과 성장배당 데이터 가져오는 중안정적인 배당: 과거에 SPL 의 주당 배당금이 안정적이었는지 판단하기에는 데이터가 부족합니다.배당금 증가: SPL 의 배당금 지급이 증가했는지 판단하기에는 데이터가 부족합니다.배당 수익률 vs 시장Sitara Peroxide 배당 수익률 vs 시장SPL의 배당 수익률은 시장과 어떻게 비교되나요?구분배당 수익률회사 (SPL)n/a시장 하위 25% (PK)2.4%시장 상위 25% (PK)7.7%업계 평균 (Chemicals)6.8%분석가 예측 (SPL) (최대 3년)n/a주목할만한 배당금: 회사가 최근 지급을 보고하지 않았기 때문에 하위 25%의 배당금 지급자에 대해 SPL 의 배당 수익률을 평가할 수 없습니다.고배당: 회사가 최근 지급을 보고하지 않았기 때문에 배당금 지급자의 상위 25%에 대해 SPL 의 배당 수익률을 평가할 수 없습니다.주주 대상 이익 배당수익 보장: 배당금 지급이 수익으로 충당되는지 확인하기 위해 SPL 의 지급 비율을 계산하기에는 데이터가 부족합니다.주주 현금 배당현금 흐름 범위: SPL 에서 지급을 보고하지 않았기 때문에 배당 지속 가능성을 계산할 수 없습니다.높은 배당을 제공하는 우량 기업 찾기7D1Y7D1Y7D1YPK 시장에서 배당이 강한 기업.View Management기업 분석 및 재무 데이터 상태데이터최종 업데이트 (UTC 시간)기업 분석2026/05/20 03:34종가2026/05/20 00:00수익2026/03/31연간 수익2025/06/30데이터 소스당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.패키지데이터기간미국 소스 예시 *기업 재무제표10년손익계산서현금흐름표대차대조표SEC 양식 10-KSEC 양식 10-Q분석가 컨센서스 추정치+3년재무 예측분석가 목표주가분석가 리서치 보고서Blue Matrix시장 가격30년주가배당, 분할 및 기타 조치ICE 시장 데이터SEC 양식 S-1지분 구조10년주요 주주내부자 거래SEC 양식 4SEC 양식 13D경영진10년리더십 팀이사회SEC 양식 10-KSEC 양식 DEF 14A주요 개발10년회사 공시SEC 양식 8-K* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.분석 모델 및 스노우플레이크이 보고서를 생성하는 데 사용된 분석 모델에 대한 자세한 내용은 당사의 Github 페이지에서 확인하실 수 있습니다. 또한 보고서 활용 방법에 대한 가이드와 YouTube 튜토리얼도 제공합니다.Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.산업 및 섹터 지표산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.분석가 소스Sitara Peroxide Limited는 2명의 분석가가 다루고 있습니다. 이 중 0명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.분석가기관Noor ShaikhBMA Capital Management Ltd.null nullInsight Securities (Private) Limited
Valuation Update With 7 Day Price Move • Apr 27Investor sentiment improves as stock rises 15%After last week's 15% share price gain to PK₨59.90, the stock trades at a trailing P/E ratio of 22.1x. Average trailing P/E is 11x in the Chemicals industry in Pakistan. Total returns to shareholders of 328% over the past three years.
공시 • Apr 22Sitara Peroxide Limited to Report Q3, 2026 Results on Apr 29, 2026Sitara Peroxide Limited announced that they will report Q3, 2026 results on Apr 29, 2026
공시 • Feb 24Sitara Peroxide Limited to Report First Half, 2026 Results on Feb 28, 2026Sitara Peroxide Limited announced that they will report first half, 2026 results on Feb 28, 2026
New Risk • Feb 17New major risk - Market cap sizeThe company's market capitalization is less than US$10m. Market cap: PK₨2.79b (US$9.97m) This is considered a major risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (14% average weekly change). Earnings have declined by 25% per year over the past 5 years. Revenue is less than US$1m. Market cap is less than US$10m (PK₨2.79b market cap, or US$9.97m).
Board Change • Feb 13Less than half of directors are independentFollowing the recent departure of a director, there are only 2 independent directors on the board. The company's board is composed of: 2 independent directors. 5 non-independent directors. Independent Director Saim Bin Saeed was the last independent director to join the board, commencing their role in 2022. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.
공시 • Jan 20Sitara Peroxide Limited to Report Q1, 2026 Results on Jan 27, 2026Sitara Peroxide Limited announced that they will report Q1, 2026 results at 12:30 PM, Pakistan Standard Time on Jan 27, 2026
공시 • Jan 08Sitara Peroxide Limited Announces Directorate AppointmentsSitara Peroxide Limited, at the EGM held on January 7, 2026 approved appointment of Mr. Muhammad Bin Imran and Mr. Muhammad Iqbal as directors.
공시 • Oct 31Sitara Peroxide Limited to Report Fiscal Year 2025 Results on Nov 07, 2025Sitara Peroxide Limited announced that they will report fiscal year 2025 results at 9:30 AM, Pakistan Standard Time on Nov 07, 2025
New Risk • Sep 12New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of Pakistani stocks, typically moving 9.3% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (9.3% average weekly change). Revenue has declined by 98% over the past year. Revenue is less than US$1m (PK₨15m revenue, or US$53k). Market cap is less than US$10m (PK₨1.45b market cap, or US$5.14m).
New Risk • Aug 09New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Pakistani stocks, typically moving 8.5% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risks Revenue has declined by 98% over the past year. Revenue is less than US$1m (PK₨15m revenue, or US$53k). Market cap is less than US$10m (PK₨970.9m market cap, or US$3.44m). Minor Risk Share price has been volatile over the past 3 months (8.5% average weekly change).
공시 • Aug 01Sitara Peroxide Limited, Annual General Meeting, Aug 22, 2025Sitara Peroxide Limited, Annual General Meeting, Aug 22, 2025.
New Risk • Jul 01New major risk - Financial data availabilityThe company has not reported any financial data. This is considered a major risk. With no or incomplete audited reported financial data, it is virtually impossible to assess the company's investment potential. Currently, the following risks have been identified for the company: Major Risks No financial data reported. Market cap is less than US$10m (PK₨820.4m market cap, or US$2.89m).
New Risk • Mar 30New major risk - Financial data availabilityThe company has not reported any financial data. This is considered a major risk. With no or incomplete audited reported financial data, it is virtually impossible to assess the company's investment potential. Currently, the following risks have been identified for the company: Major Risks No financial data reported. Market cap is less than US$10m (PK₨664.0m market cap, or US$2.37m).
Reported Earnings • Dec 19First quarter 2024 earnings released: PK₨1.43 loss per share (vs PK₨1.98 loss in 1Q 2023)First quarter 2024 results: PK₨1.43 loss per share (improved from PK₨1.98 loss in 1Q 2023). Revenue: PK₨15.9m (down 95% from 1Q 2023). Net loss: PK₨78.8m (loss narrowed 28% from 1Q 2023).
Reported Earnings • Sep 27Full year 2023 earnings released: PK₨14.39 loss per share (vs PK₨6.19 loss in FY 2022)Full year 2023 results: PK₨14.39 loss per share (further deteriorated from PK₨6.19 loss in FY 2022). Revenue: PK₨824.0m (down 53% from FY 2022). Net loss: PK₨792.8m (loss widened 132% from FY 2022).
공시 • Sep 27Sitara Peroxide Limited, Annual General Meeting, Oct 10, 2024Sitara Peroxide Limited, Annual General Meeting, Oct 10, 2024.
New Risk • Aug 26New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Pakistani stocks, typically moving 7.0% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risks Latest financial reports are more than 1 year old (reported March 2023 fiscal period end). Revenue has declined by 64% over the past year. Market cap is less than US$10m (PK₨783.0m market cap, or US$2.81m). Minor Risks Share price has been volatile over the past 3 months (7.0% average weekly change). Revenue is less than US$5m (PK₨720m revenue, or US$2.6m).
공시 • Jul 23Sitara Peroxide Limited, Annual General Meeting, Jul 26, 2024Sitara Peroxide Limited, Annual General Meeting, Jul 26, 2024, at 15:00 Pakistan Standard Time. Agenda: To consider the pending approval of the audited financial statments along with subsequent developments and way-forward; to consider the pending approval of the balancing, modernization and replacement of the company, the financial arrangementas and way-forward; and to consider other matters.
New Risk • May 05New major risk - Financial data availabilityThe company's latest financial reports are more than a year old. Last reported fiscal period ended March 2023. This is considered a major risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. In the worst case scenario, it may be facing other major going concern issues jeopardizing its viability as a listed company. Currently, the following risks have been identified for the company: Major Risks Latest financial reports are more than 1 year old (reported March 2023 fiscal period end). Revenue has declined by 64% over the past year. Market cap is less than US$10m (PK₨771.4m market cap, or US$2.77m). Minor Risk Revenue is less than US$5m (PK₨720m revenue, or US$2.6m).
New Risk • Nov 21New minor risk - Financial data availabilityThe company's latest financial reports are more than 6 months old. Last reported fiscal period ended March 2023. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-PK₨139m free cash flow). Share price has been highly volatile over the past 3 months (8.8% average weekly change). Earnings have declined by 56% per year over the past 5 years. Market cap is less than US$10m (PK₨933.9m market cap, or US$3.27m). Minor Risks Latest financial reports are more than 6 months old (reported March 2023 fiscal period end). Revenue is less than US$5m (PK₨720m revenue, or US$2.5m).
New Risk • Oct 18New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Pakistani stocks, typically moving 6.2% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-PK₨139m free cash flow). Earnings have declined by 56% per year over the past 5 years. Market cap is less than US$10m (PK₨750.5m market cap, or US$2.71m). Minor Risks Share price has been volatile over the past 3 months (6.2% average weekly change). Revenue is less than US$5m (PK₨720m revenue, or US$2.6m).
Reported Earnings • Apr 08Second quarter 2023 earnings released: PK₨2.01 loss per share (vs PK₨0.13 profit in 2Q 2022)Second quarter 2023 results: PK₨2.01 loss per share (down from PK₨0.13 profit in 2Q 2022). Revenue: PK₨70.6m (down 89% from 2Q 2022). Net loss: PK₨111.0m (down PK₨118.2m from profit in 2Q 2022). Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 101 percentage points per year, which is a significant difference in performance.
Board Change • Nov 16Less than half of directors are independentThere is 1 new director who has joined the board in the last 3 years. The new board member was an independent director. The company's board is composed of: 1 new director. 6 experienced directors. No highly experienced directors. 2 independent directors (5 non-independent directors). Independent Director Saim Bin Saeed was the last independent director to join the board, commencing their role in 2022. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment.
공시 • Nov 12Sitara Peroxide Limited Appoints Yasir Ahmed Awan as ChairmanSitara Peroxide Limited announced that Mr. Yasir Ahmed Awan has been appointed as Chairman of the Board of Directors of the Company and Mr. Imran Ghafoor as Chief Executive Officer for a term of three years.
공시 • Aug 19Sitara Peroxide Limited Appoints Saim Bin Saeed as DirectorSitara Peroxide Limited informed Pakistan Stock Exchange that Mr. Saim Bin Saeed has been appointed as Director of the company with effect from August 17, 2022 in place of Mr. Mahmood Ahmad.
공시 • Jun 03Sitara Peroxide Limited Announces Resignation of Mahmood Ahmad as DirectorSitara Peroxide Limited informed Pakistan Stock Exchange that Mr. Mahmood Ahmad has resigned from the post of Director of the company with effect from May 30, 2022.
Board Change • Apr 27Less than half of directors are independentNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 7 experienced directors. No highly experienced directors. 2 independent directors (5 non-independent directors). Non-Executive Director Ejaz Hussain was the last director to join the board, commencing their role in 2016. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment.
Reported Earnings • Nov 01First quarter 2022 earnings released: PK₨1.80 loss per share (vs PK₨0.92 profit in 1Q 2021)The company reported a poor first quarter result with weaker earnings, revenues and control over costs. First quarter 2022 results: Revenue: PK₨450.5m (down 21% from 1Q 2021). Net loss: PK₨99.0m (down 294% from profit in 1Q 2021). Over the last 3 years on average, earnings per share has fallen by 49% per year but the company’s share price has only fallen by 15% per year, which means it has not declined as severely as earnings.
Price Target Changed • Oct 07Price target decreased to PK₨31.00Down from PK₨36.50, the current price target is provided by 1 analyst. New target price is 43% above last closing price of PK₨21.62. Stock is down 6.3% over the past year.
Reported Earnings • Sep 28Full year 2021 earnings released: EPS PK₨0.63 (vs PK₨1.35 in FY 2020)The company reported a soft full year result with weaker earnings and profit margins, although revenues improved. Full year 2021 results: Revenue: PK₨1.87b (up 6.9% from FY 2020). Net income: PK₨34.7m (down 53% from FY 2020). Profit margin: 1.9% (down from 4.3% in FY 2020). Over the last 3 years on average, earnings per share has fallen by 5% per year but the company’s share price has fallen by 14% per year, which means it is performing significantly worse than earnings.
Valuation Update With 7 Day Price Move • Sep 27Investor sentiment deteriorated over the past weekAfter last week's 16% share price decline to PK₨21.00, the stock trades at a trailing P/E ratio of 5.7x. Average forward P/E is 17x in the Chemicals industry in Pakistan. Total loss to shareholders of 32% over the past three years.
Executive Departure • Jul 13Chief Financial Officer Kamran Zahoor has left the companyDuring their tenure, the company went from making losses to turning a profit. On the 30th of June, Kamran Zahoor left the company after 3.3 in the role. We don't have any record of a personal shareholding under Kamran's name. Kamran is the only executive to leave the company over the last 12 months.
Reported Earnings • May 02Third quarter 2021 earnings released: EPS PK₨0.44 (vs PK₨0.15 in 3Q 2020)The company reported a decent third quarter result with improved earnings and profit margins, although revenues were weaker. Third quarter 2021 results: Revenue: PK₨447.8m (down 3.8% from 3Q 2020). Net income: PK₨24.3m (up 200% from 3Q 2020). Profit margin: 5.4% (up from 1.7% in 3Q 2020). The increase in margin was driven by lower expenses. Over the last 3 years on average, earnings per share has increased by 30% per year but the company’s share price has only increased by 8% per year, which means it is significantly lagging earnings growth.
Reported Earnings • Feb 28Second quarter 2021 earnings released: EPS PK₨0.83 (vs PK₨0.40 loss in 2Q 2020)The company reported a decent second quarter result with improved earnings and profit margins, although revenues were weaker. Second quarter 2021 results: Revenue: PK₨497.2m (down 7.4% from 2Q 2020). Net income: PK₨45.6m (up PK₨67.8m from 2Q 2020). Profit margin: 9.2% (up from net loss in 2Q 2020). The move to profitability was driven by lower expenses. Over the last 3 years on average, earnings per share has increased by 43% per year but the company’s share price has only increased by 19% per year, which means it is significantly lagging earnings growth.
Valuation Update With 7 Day Price Move • Feb 01Investor sentiment improved over the past weekAfter last week's 19% share price gain to PK₨32.76, the stock is trading at a trailing P/E ratio of 15.3x, up from the previous P/E ratio of 12.8x. This compares to an average P/E of 14x in the Chemicals industry in Pakistan. Total returns to shareholders over the past three years are 66%.
Is New 90 Day High Low • Jan 27New 90-day high: PK₨30.16The company is up 36% from its price of PK₨22.13 on 29 October 2020. The Pakistani market is up 10.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Chemicals industry, which is up 5.0% over the same period.
Valuation Update With 7 Day Price Move • Jan 06Investor sentiment improved over the past weekAfter last week's 17% share price gain to PK₨26.91, the stock is trading at a trailing P/E ratio of 12.5x, up from the previous P/E ratio of 10.7x. This compares to an average P/E of 13x in the Chemicals industry in Pakistan. Total returns to shareholders over the past three years are 59%.
Is New 90 Day High Low • Jan 05New 90-day high: PK₨25.04The company is up 8.0% from its price of PK₨23.22 on 07 October 2020. The Pakistani market is up 11% over the last 90 days, indicating the company underperformed over that time. However, it outperformed the Chemicals industry, which is up 7.0% over the same period.
Reported Earnings • Oct 23First quarter earnings releasedOver the last 12 months the company has reported total profits of PK₨119.9m, up 67% from the prior year. Total revenue was PK₨1.92b over the last 12 months, up 2.3% from the prior year.
Reported Earnings • Oct 06Full year earnings released - EPS PK₨1.35Over the last 12 months the company has reported total profits of PK₨74.2m, down 64% from the prior year. Total revenue was PK₨1.75b over the last 12 months, down 14% from the prior year. Profit margins were 4.3%, which is lower than the 10% margin from last year. The decrease in margin was driven by lower revenue.
Reported Earnings • Sep 30Full year earnings released - EPS PK₨1.35Over the last 12 months the company has reported total profits of PK₨74.2m, down 64% from the prior year. Total revenue was PK₨1.75b over the last 12 months, down 14% from the prior year. Profit margins were 4.3%, which is lower than the 10% margin from last year. The decrease in margin was driven by lower revenue.